Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
24.69
-0.29 (-1.16%)
At close: Apr 28, 2026, 4:00 PM EDT
24.69
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:15 PM EDT
Castle Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Castle Biosciences stock have an average target of 45.5, with a low estimate of 40 and a high estimate of 52. The average target predicts an increase of 84.29% from the current stock price of 24.69.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Castle Biosciences stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 4 | 3 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $50 → $40 | Strong Buy | Maintains | $50 → $40 | +62.01% | Apr 20, 2026 |
| Baird | Baird | Buy Maintains $41 → $44 | Buy | Maintains | $41 → $44 | +78.21% | Feb 27, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $43 → $47 | Strong Buy | Maintains | $43 → $47 | +90.36% | Jan 26, 2026 |
| Lake Street | Lake Street | Strong Buy Maintains $35 → $52 | Strong Buy | Maintains | $35 → $52 | +110.61% | Jan 12, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $30 → $43 | Strong Buy | Maintains | $30 → $43 | +74.16% | Jan 5, 2026 |
Financial Forecast
Revenue This Year
352.55M
from 344.23M
Increased by 2.42%
Revenue Next Year
397.29M
from 352.55M
Increased by 12.69%
EPS This Year
-1.16
from -0.83
EPS Next Year
-0.55
from -1.16
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 365.4M | 419.3M | ||||||
| Avg | 352.6M | 397.3M | ||||||
| Low | 337.4M | 376.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 6.1% | 18.9% | ||||||
| Avg | 2.4% | 12.7% | ||||||
| Low | -2.0% | 6.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | -0.83 | -0.19 | ||||
| Avg | -1.16 | -0.55 | ||||
| Low | -1.40 | -0.83 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.